In CMS patients due to COLQ, DOK7 and LAMB2 mutations sympathomimetics like ephedrine and salbutamol have been shown to have a clear beneficial effect without major side effects [21,22]. This evidence concerns the gene LAMB2 and congenital myasthenic syndrome.